Detalhe da pesquisa
1.
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
EBioMedicine
; 85: 104298, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36229342